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Patients with relapsed peripheral T-cell non-Hodgkin's lymphoma (T-NHL) carry a particularly dismal prognosis, and although this lymphoma is often chemosensitive, optimal therapeutic strategies are yet to be defined.
1 To achieve remission, immunotherapy with the CD20 antibody rituximab is a valuable adjunct to chemotherapy in aggressive B-cell lymphomas.
2,3 By analogy, the CD52 antibody alemtuzumab has some activity against T-NHL as a single agent, for example in T-cell prolymphocytic leukaemia (T-PLL), although it has not been systematically evaluated in combinations. 4 As for consolidation, highdose chemotherapy followed by stem cell transplantation is a feasible strategy against peripheral T-NHL. 5 In the allogeneic setting, recent studies have reported reduced intensity conditioning (RIC) as an efficient platform for graft-versus-lymphoma (GvL) activity. [6] [7] [8] We here report our experience with allogeneic stem cell transplantation after RIC following salvage therapy combining chemotherapy and alemtuzumab for patients with peripheral T-NHL.
Between August 2003 and January 2005, 10 consecutive patients with relapsed or primary progressive T-NHL were treated with combined chemotherapy/alemtuzumab salvage therapy followed by allogeneic stem cell transplantation at our institution. The median age at diagnosis was 45 years, range 23-53 years (Table 1) . Histological classifications were peripheral T-cell lymphoma not otherwise specified in four cases, large-cell T-cell lymphoma in three cases, angioimmunoblastic lymphoma (AILD) in two cases, and T-PLL in one patient. All patients experienced progression or relapse at a median interval of 2.5 (range 0-26) months after CHOP-like primary chemotherapy. In four cases, several (range 2-5) salvage regimens were used, including high-dose chemotherapy with autologous stem cell transplantation in two. Alemtuzumab was given as a single agent in two, and in combination with chemotherapy in eight cases, respectively. Doses were 3, 10 and 30 mg q 48 h in the first week, followed by 30 mg q 48 h up to maximal response when given as a single agent. In the cases of chemotherapy/ alemtuzumab combinations, patients received the loading dose of 43 mg in the first course of chemotherapy, and 3 Â 30 mg q 48 h with each further cycle. Alemtuzumab was reduced or stopped in cases of oWHO grade II toxic reactions to the antibody. The cumulative doses of alemtuzumab are listed in Table 1 ; the minimal interval of alemtuzumab application prior to transplantation was 21 days. The chemotherapy regimens given in conjunction with alemtuzumab were ifosphamide/carboplatin/etoposide (ICE) 9 in seven cases, and cyclophosphamide/fludarabine/ daunorubicin in one case (case 3) 10 . Overall response to alemtuzumab-containing therapy was complete remission (CR) in the patient with T-PLL, partial remission (PR) in five cases, as well as stable (SD) and progressive disease (PD) in two cases each (Table 1) .
Following alemtuzumab-containing therapy, all patients were judged eligible for allogeneic stem cell transplantation after RIC. RIC comprised fludarabine (5 Â 25 mg/m 2 ), oral busulfan (12 mg/kg body weight) and cyclophosphamide (2 Â 60 mg/m 2 ) as previously described, 8 followed by transplantation of 5.171.5 (range 3.0-7.9) Â 10 6 /kg body weight CD34 positive peripheral blood stem cells. The stem cells had been obtained from HLA-identical siblings in four, and matched unrelated donors in six patients. Graftversus-host disease (GvHD) prophylaxis consisted of tacrolimus from day-1 through 180, and mycophenolate 3 Â 500 mg daily from day À1 through 28. All patients engrafted, with a median time to neutrophil (o0.5 Â 10 9 /l) recovery of 872.3 (range 7-12) days. One patient died on day 12 from cardiac arrest. One patient experienced grade III acute GvHD, three patients grade II, and one patient grade I, whereas four patients developed no signs of aGvHD. Chronic GvHD was either extensive in five patients, including two fatal complications (intestinal in case 9 and pulmonary in case 11), or completely absent in four cases. Infectious complications X grade III within the first 100 days after transplantation occurred in four patients, all of which were manageable by antibiotic/ antiviral therapy. Of those, one patient experienced systemic CMV reactivation with pulmonary dysfunction.
With a median follow-up time of 7 (range 4-16) months after SCT, seven patients are alive, six patients are in CR, and one patient had cerebral relapse 4 months after SCT.
What are the conclusions from this case series?
First, combining anti-CD52 antibody therapy with chemotherapy in peripheral T-NHL appears feasible. Despite substantial immunosuppression by disease and extensive prior chemotherapy, we did not observe significant infectious complications during alemtuzumab-containing salvage therapy. In particular, there was no CMV reactivation in this cohort, although eight of 10 patients exhibited anti-CMV seropositivity. As for the efficacy of alemtuzumab against T-NHL in this setting, no firm conclusions can be drawn. Improved outcome due to alemtuzumab was documented in two patients: alemtuzumab induced CR in one patient with T-PLL who had failed three prior chemotherapies. Furthermore, in patient 4, one course of ICE chemotherapy led to SD, but PR was achieved in a second course of ICE in combination with alemtuzumab. The efficacy of alemtuzumab against T-PLL was not surprising, as the antibody produced remissions in two-thirds of patients with this disease when used as a single agent. 11 In all other cases, a clear attribution of efficacy to alemtuzumab was not possible, as the cumulative dose of alemtuzumab differed widely between patients. Given the poor prospects of relapsed T-NHL, in general, and the aggressive course of disease in the patients of this cohort, however, the results are encouraging. Immunotherapy with alemtuzumab may evolve as a helpful adjunct to chemotherapy, allowing patients with T-NHL to achieve PR prior to definitive high-dose chemotherapy followed by stem cell transplantation.
Second, RIC and allogeneic stem cell transplantation was feasible in this group of patients. Of the four patients in SD and five patients in PR after salvage therapy, treatment with the FBC-12 regimen and allogeneic stem cell transplantation induced CR at day 100 post transplantation in six cases. The relative contributions of the cytostatic effect of the FBC-12 regimen and GvL effect remain unclear. Two patients experienced a relapse; intriguingly, both of them lacked any prior signs of chronic GvHD. One patient received donor lymphocyte infusions (DLI), and is currently under follow up. In another study, DLI induced CR in a patient with relapsed T-NHL after allogeneic transplantation. 12 Corradini et al 13 also observed responses to DLI in two patients with relapsed T-NHL after allogeneic stem cell transplantation, providing more direct evidence for potential GvL activity against T-NHL.
In summary, therapeutic strategies with regimens integrating antibodies, such as alemtuzumab, followed by RIC and allogeneic stem cell transplantation appear feasible, and warrant further prospective evaluation for patients with relapsed peripheral T-NHL. Correspondence
